RAIN RAIN THERAPEUTICS INC

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:

Date: March 9, 2023

Time: 2:00 PT (5:00 pm ET)

Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920 (International)

Conference ID: 13735982

Webcast Link:

Replay of the call will be available by visiting the "" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Oncology Inc.

Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact

Jordyn Temperato

LifeSci Communications

Investor Contact

Dan Ferry

LifeSci Advisors

+1.617.430.7576



EN
23/02/2023

Underlying

RAINRAIN THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAIN THERAPEUTICS INC

 PRESS RELEASE
Free
RAIN RAIN THERAPEUTI...

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1...

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions c...

December 13, 2023 1 EN
 PRESS RELEASE
Free
RAIN RAIN THERAPEUTI...

Rain Oncology Reports Third Quarter 2023 Financial Results and Provide...

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We anticipate being able to provide a public update on our efforts before th...

November 9, 2023 1 EN
 PRESS RELEASE
Free
RAIN RAIN THERAPEUTI...

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra ...

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs. Rain’s Board of Directors and management team regularly r...

October 16, 2023 1 EN
 PRESS RELEASE
Free
RAIN RAIN THERAPEUTI...

Rain Oncology Reports Second Quarter 2023 Financial Results and Provid...

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain)...

August 10, 2023 1 EN
 PRESS RELEASE
Free
RAIN RAIN THERAPEUTI...

Rain Oncology to Report Second Quarter 2023 Financial Results and Prov...

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023 NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm...

July 26, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch